Plasma levels of cAMP, cGMP and CGRP in sildenafil-induced headache
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Plasma levels of cAMP, cGMP and CGRP in sildenafil-induced headache. / Kruuse, Christina Rostrup; Frandsen, E; Schifter, S; Thomsen, L L; Birk, S; Olesen, J.
In: Cephalalgia : an international journal of headache, Vol. 24, No. 7, 07.2004, p. 547-53.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Plasma levels of cAMP, cGMP and CGRP in sildenafil-induced headache
AU - Kruuse, Christina Rostrup
AU - Frandsen, E
AU - Schifter, S
AU - Thomsen, L L
AU - Birk, S
AU - Olesen, J.
PY - 2004/7
Y1 - 2004/7
N2 - Sildenafil, a selective inhibitor of the cyclic guanosine monophosphate (cGMP) degrading phosphodiestrase 5 (PDE5), induced migraine without aura in 10 of 12 migraine patients and in healthy subjects it induced significantly more headache than placebo. The aim of the present study was to determine whether the pain-inducing effects of sildenafil would be reflected in plasma levels of important signalling molecules in migraine: cGMP, cyclic adenosine monophosphate (cAMP) and calcitonin gene-related peptide (CGRP). Ten healthy subjects (four women, six men) and 12 patients (12 women) suffering from migraine without aura were included in two separate double-blind, placebo-controlled, cross-over studies in which placebo or sildenafil 100 mg was administered orally. Plasma levels of CGRP, cAMP and cGMP were determined in blood from the antecubital vein. Despite the ability of sildenafil to induce headache and migraine, no significant differences in plasma levels of CGRP, cGMP and cAMP were detected after sildenafil compared with placebo. In conclusion, plasma levels of CGRP, cGMP and cAMP remain normal during sildenafil-induced headache or migraine. However, since previous studies indicate an important role of these signalling molecules, the present study questions whether cAMP and cGMP in peripheral blood can be used for monitoring pathophysiological events in headache and migraine mechanisms.
AB - Sildenafil, a selective inhibitor of the cyclic guanosine monophosphate (cGMP) degrading phosphodiestrase 5 (PDE5), induced migraine without aura in 10 of 12 migraine patients and in healthy subjects it induced significantly more headache than placebo. The aim of the present study was to determine whether the pain-inducing effects of sildenafil would be reflected in plasma levels of important signalling molecules in migraine: cGMP, cyclic adenosine monophosphate (cAMP) and calcitonin gene-related peptide (CGRP). Ten healthy subjects (four women, six men) and 12 patients (12 women) suffering from migraine without aura were included in two separate double-blind, placebo-controlled, cross-over studies in which placebo or sildenafil 100 mg was administered orally. Plasma levels of CGRP, cAMP and cGMP were determined in blood from the antecubital vein. Despite the ability of sildenafil to induce headache and migraine, no significant differences in plasma levels of CGRP, cGMP and cAMP were detected after sildenafil compared with placebo. In conclusion, plasma levels of CGRP, cGMP and cAMP remain normal during sildenafil-induced headache or migraine. However, since previous studies indicate an important role of these signalling molecules, the present study questions whether cAMP and cGMP in peripheral blood can be used for monitoring pathophysiological events in headache and migraine mechanisms.
KW - Adult
KW - Analysis of Variance
KW - Calcitonin Gene-Related Peptide
KW - Cross-Over Studies
KW - Cyclic AMP
KW - Cyclic GMP
KW - Double-Blind Method
KW - Female
KW - Headache
KW - Humans
KW - Male
KW - Migraine without Aura
KW - Piperazines
KW - Purines
KW - Sulfones
U2 - 10.1111/j.1468-2982.2003.00712.x
DO - 10.1111/j.1468-2982.2003.00712.x
M3 - Journal article
C2 - 15196297
VL - 24
SP - 547
EP - 553
JO - Cephalalgia
JF - Cephalalgia
SN - 0800-1952
IS - 7
ER -
ID: 136683676